<DOC>
	<DOCNO>NCT01225380</DOCNO>
	<brief_summary>This phase 2b study evaluate efficacy safety 16 24 week response-guided duration therapy GS-9190 GS-9256 combination Peginterferon Alfa-2a ( Pegasys® ) Ribavirin ( Copegus® ) . Additionally , efficacy safety 24 week GS-9256 combination Peginterferon Alfa-2a ( Pegasys® ) Ribavirin ( Copegus® ) evaluate .</brief_summary>
	<brief_title>A Study Response-Guided Duration Combination Therapy With GS-9190 , GS-9256 , Pegasys® Copegus® Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult subject 18 70 year age Chronic HCV infection least 6 month prior Baseline ( Day 1 ) Liver biopsy result ( performed 2 year prior Screening ) indicate absence cirrhosis Monoinfection HCV genotype 1a 1b HCV treatmentnaïve Body mass index ( BMI ) 18 36 kg/m2 Creatinine clearance &gt; /= 50 mL/min Subject agree use highly effective contraception method female childbearing potential sexually active male . Screening laboratory value within define threshold ALT , AST , leukopenia , neutropenia , anemia , thrombocytopenia , thyroid stimulate hormone ( TSH ) , potassium , magnesium Autoimmune disease Decompensated liver disease cirrhosis Poorly control diabetes mellitus Severe psychiatric illness Severe chronic obstructive pulmonary disease ( COPD ) Serological evidence coinfection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , another HCV genotype Suspicion hepatocellular carcinoma malignancy ( exception certain skin cancer ) History hemoglobinopathy Known retinal disease Subjects immunosuppressed Subjects know , current use amphetamine , cocaine , opiate ( i.e. , morphine , heroin ) , methadone , ongoing alcohol abuse Subjects expect potent cytochrome P450 ( CYP ) 3A4 Pgp inhibitor , QT prolong medication within 2 week Baseline ( Day 1 ) study Subjects must history clinically significant cardiac disease , include family history Long QT syndrome , relevant electrocardiogram ( ECG ) abnormalities screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>GS-9190</keyword>
	<keyword>GS-9256</keyword>
</DOC>